<DOC>
	<DOCNO>NCT01887912</DOCNO>
	<brief_summary>The aim study evaluate efficacy candidate Clostridium difficile ( Cdiffense ) vaccine prevent primary symptomatic C. difficile infection ( CDI ) subject risk CDI substantial unmet medical need . Primary objective : - To assess efficacy C. difficile vaccine prevent onset symptomatic primary CDI confirm polymerase chain reaction ( PCR ) adult subject age ≥ 50 year risk CDI receive least 1 injection . Secondary Objectives : Efficacy : - To assess prevention symptomatic PCR-confirmed primary CDI case 3 injection administer 0 , 7 , 30 day - To assess prevention symptomatic PCR-confirmed primary CDI case completion least 2 injection . Immunogenicity : - To describe immunogenicity toxin A toxin B subset subject specific time point . Safety : - To describe safety profile subject receive least 1 injection .</brief_summary>
	<brief_title>Study Candidate Clostridium Difficile Toxoid Vaccine ( Cdiffense ) Subjects Risk C. Difficile Infection</brief_title>
	<detailed_description>The study design event-driven group sequential protocol 3 interim analysis define information milestone final analysis specific number clinical endpoint reach . Subjects randomly assign receive either candidate vaccine placebo administer 3-dose schedule .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged ≥ 50 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure Covered health insurance ( require ) Must fulfill least 1 follow criterion Risk Stratum 1 : Has least 2 hospital stay , last least ≥ 24 hour , 12 month enrollment , Has receive systemic ( topical ) antibiotic 12 month enrollment , Risk Stratum 2 : Is anticipated inpatient hospitalization plan surgical procedure within 60 day enrollment . The impending hospital stay plan ≥ 72 hour surgery involve 1 follow : Kidney/bladder/urinary system Musculoskeletal system Respiratory system Circulatory system Central nervous system . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior first vaccination least 4 week last vaccination ) Participation 4 week precede first trial vaccination participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination except influenza ( seasonal pandemic ) pneumococcal vaccine . This exception include monovalent pandemic influenza vaccine multivalent influenza vaccine Previous vaccination C. difficile either trial vaccine , another vaccine , monoclonal antibody Diarrhea day enrollment Selfreported current prior CDI episode Anticipated current receipt kidney dialysis treatment History gastrointestinal surgery gastrointestinal malignancy ( Note : Colonoscopy , polypectomy , appendectomy exclusion criterion . ) History inflammatory bowel disease , irritable bowel syndrome , colostomy , small large intestine bowel surgery resection perform Receiving enteral feeding ( e.g. , nasogastric , gastrostomy , jejunostomy tube feed ) Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Selfreported thrombocytopenia , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure opinion Investigator Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 38.0°C [ ≥ 100.4°F ] ) . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Clostridium difficile Toxoid Vaccine</keyword>
	<keyword>Clostridium difficile infection</keyword>
	<keyword>Cdiffense</keyword>
</DOC>